GlobeNewswire
Recludix Pharma Announces FDA Clearance of Investigational New Drug Application for REX-8756, an Oral STAT6 Inhibitor, to Enter into the Clinic
📈
AI Sentiment
Highly Positive
9/10
- Home
- SNY
SNY
Sanofi ADS
as of 12-17-2025 11:17am EST
$47.92
+$0.48
+1.00%
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
Chart Type:
Time Range:
| Founded: | 1994 | Country: | France |
| Employees: | N/A | City: | N/A |
| Market Cap: | 119.4B | IPO Year: | N/A |
| Target Price: | $61.50 | AVG Volume (30 days): | 2.8M |
| Analyst Decision: | Buy | Number of Analysts: | 5 |
| Dividend Yield: | Dividend Payout Frequency: | Annual | |
| EPS: | 8.67 | EPS Growth: | 105.93 |
| 52 Week Low/High: | $44.62 - $60.12 | Next Earning Date: | 01-29-2026 |
| Revenue: | $53,890,648,839 | Revenue Growth: | -5.19% |
| Revenue Growth (this year): | 2.48% | Revenue Growth (next year): | 6.47% |
Latest Sanofi ADS News
SNY Breaking Stock News: Dive into SNY Ticker-Specific Updates for Smart Investing
PR Newswire
ADEL Signs $1.04 Billion Global License Agreement with Sanofi for ADEL-Y01, a Novel investigational Alzheimer's Disease Therapy
📈
AI Sentiment
Highly Positive
9/10
The Wall Street Journal
Stocks to Watch Monday: iRobot, EchoStar, Juventus
⚠️
AI Sentiment
Highly Negative
1/10
MT Newswires
Sanofi, Dren Bio Collaborate on Next-Gen B-Cell Therapy for Autoimmune Diseases
📈
AI Sentiment
Highly Positive
8/10
Business Wire
Dren Bio Expands Strategic Collaboration with Sanofi to Develop Next-Generation B-Cell Depletion Therapy
📈
AI Sentiment
Highly Positive
9/10
Clinical Trials Arena
Sanofi shares fall 6% after double setback for MS drug tolebrutinib
📉
AI Sentiment
Negative
2/10
MT Newswires
Sanofi Says FDA Delayed Review for Tolebrutinib in Non-Relapsing Secondary Progressive Multiple Sclerosis
➖
AI Sentiment
Neutral
5/10
Compare SNY vs Leading Stocks
See how SNY stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "SNY Sanofi ADS - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.